Wednesday, July 8, 2026

Patent intelligence · US

US 9526882

Percutaneous administration device and method for producing the same

granted A61KA61K2800/87A61K8/676A61K9/703
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 10
Applicant portfolio 158
Patent details — US 9526882
Jurisdiction
US
Status
granted
Grant date
Dec 27, 2016
Expiration
Dec 22, 2036
Claims
8
CPC classes
A61K, A61K2800/87, A61K8/676, A61K9/703
View on Google Patents ↗

Quick answer

US 9526882 (Percutaneous administration device and method for producing the same) is held by OPTNICS PRECISION CO., LTD.. Status: granted. Granted Dec 27, 2016. Expires Dec 22, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
8
CPC classes
A61K, A61K2800/87, A61K8/676, A61K9/703, A61K9/7084, A61K9/7092

More from OPTNICS PRECISION CO., LTD.

Related pharmaceutical patents in our USPTO index.

  1. US 12419920

    Bifidobacterium longum NCIMB 41676

    PrecisionBiotics Group Limited · Expires Sep 18, 2045

    granted
  2. US 12410418

    Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome

    Precision BioSciences, Inc. · Expires Sep 4, 2045

    granted
  3. US 12351839

    Rationally-designed single-chain meganucleases with non-palindromic recognition sequences

    Precision BioSciences, Inc. · Expires Jul 3, 2045

    granted
  4. US 12344676

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Expires Jun 26, 2045

    granted
  5. US 12336835

    Neuromodulation to target glucose transporter and/or incretin pathways

    GE Precision Healthcare LLC · Expires Jun 19, 2045

    granted
  6. US 12232492

    Disinfection of bacteriophages products using supercritical carbon dioxide

    PRECISIONBIOTIX TECHNOLOGIES INC. · Expires Feb 20, 2045

    granted
  7. US 12233135

    Therapeutic constructs for treating cancer

    PRECISION MOLECULAR INC. · Expires Feb 20, 2045

    granted
  8. US 12180463

    Lactobacillus reuteri

    PrecisionBiotics Group Limited · Expires Dec 26, 2044

    granted

Frequently asked questions

What is US patent 9526882?

US 9526882 (Percutaneous administration device and method for producing the same) is held by OPTNICS PRECISION CO., LTD.. Status: granted. Granted Dec 27, 2016. Expires Dec 22, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9526882?

OPTNICS PRECISION CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 158 pharmaceutical patents for this assignee.

When does US 9526882 expire?

Our index shows an expiration date of Dec 22, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.